Fri, 07 Dec 2018 13:43:56: DiaMedica pulls off IPO to fund midphase stroke trial

Fri, 07 Dec 2018 11:53:54: Moderna’s cash juggernaut rolls on with record $604M IPO

Fri, 07 Dec 2018 11:04:27: AstraZeneca’s tremelimumab fails another phase 3 cancer trial

Thu, 06 Dec 2018 23:18:22: Chutes & Ladders—Xenotransplantation firm eGenesis hires new R&D head

Thu, 06 Dec 2018 15:32:45: Supernus’ stocks down once more, despite positive phase 3 ADHD data for SPN-812

Thu, 06 Dec 2018 13:51:16: Genfit’s elafibranor hits goal in phase 2 PBC trial

Thu, 06 Dec 2018 13:24:43: Impel raises $67.5M as it eyes filing for nasal migraine drug

Thu, 06 Dec 2018 13:10:48: Midphase failure of Novartis’ NASH drug crushes Conatus

Thu, 06 Dec 2018 11:48:33: Regenerating insulin-producing cells with zinc could tackle the underlying cause of diabetes

Wed, 05 Dec 2018 20:34:38: Xenotransplantation firm eGenesis hires Wes Westlin as R&D head

Wed, 05 Dec 2018 15:40:37: Could blocking a single gene cure obesity without diet and exercise?

Wed, 05 Dec 2018 14:09:31: U.K. sets out digital, data-driven plan to accelerate R&D

Wed, 05 Dec 2018 14:01:26: ASH18: Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field

Wed, 05 Dec 2018 13:27:34: UCB to spend £200M to create U.K. R&D hub

Tue, 04 Dec 2018 17:45:12: Relay adds executives to its chemistry, R&D teams as it transitions to the development stage

Tue, 04 Dec 2018 14:41:06: SmartZyme spins off protein tech company for a metabolic disease partnership with Hemoshear

Tue, 04 Dec 2018 13:44:29: With Gilead and rivals deep in phase 3, FDA unveils draft guidance on NASH drug development

Tue, 04 Dec 2018 13:36:17: Boehringer inks pact with Domain for GPCR neurology drugs

Tue, 04 Dec 2018 12:01:24: ASH18: Amgen’s anti-BCMA bispecific shines again, but CAR-T threat remains

Mon, 03 Dec 2018 16:22:40: Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders

Mon, 03 Dec 2018 14:16:52: Regeneron records 80% complete response rate in lymphoma trial

Mon, 03 Dec 2018 13:26:25: ASH18: New data can’t lift Bluebird Bio’s depressed shares

Mon, 03 Dec 2018 09:55:47: ASH18: J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab

Fri, 30 Nov 2018 17:11:23: Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH

Fri, 30 Nov 2018 13:56:20: Principia chalks up a win for its BTK autoimmune program